This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Nonadherence with medication treatment is common but difficult to detect in patients with schizoaffective disorder and schizophrenia, almost half of whom take less than 70% of prescribed doses. Like patients in all areas of medicine, patients with schizoaffective disorder weigh the perceived benefits of medications against perceived disadvantages, but this process is complicated by their impaired insight, the stigma of the diagnosis, and the often troubling side effects of antipsychotic medication. Interventions to improve adherence include encouraging acceptance of the illness, drawing analogies with treatment for chronic medical disease, and involving the patient in decision making. Clinicians must remain nonjudgmental, encouraging patients to disclose problems with adherence and anticipating that improvement in adherence may require a prolonged effort. Selection of antipsychotic medication is critical to avoid adverse side effects, and some medications may provide a sense of well-being, such as improvement in insomnia, anxiety, or depression. Depot (rather than oral) antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received, which can be used for purposes of dose adjustments or to guide response to relapse.

(J Clin Psychiatry 2010;71[suppl 2]:20-26)

From the Schizophrenia Program, Harvard Medical School and Massachusetts General Hospital, Boston.

This article was supported by an educational grant from Janssen, Division of Ortho-McNeill-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeill Janssen Scientific Affairs, LLC.

Dr Goff is a consultant for Schering-Plough, Eli Lilly, F. Hoffman-La Roche, Takeda, Biovail, Solvay, and Dainippon Sumitomo; has received grant/research support from GlaxoSmithKline, Novartis, and Pfizer; and has received other financial support from Otsuka (Data Safety Monitoring Board). Dr Freudenreich is a consultant for Beacon Health Strategies, has received grant/research support from Pfizer, has received honoraria from Reed Medical Education, and has received other financial support from Lippincott Williams & Wilkins. Dr Hill has no personal affiliations or financial relationships with any commercial interest to disclose relative to this article.

Corresponding author: Donald C. Goff, MD, Freedom Trail Clinic, 25 Staniford St, Boston, MA 02114 (

A recent editorial1 noted that as many as half of all patients in the United States do not take medications as prescribed, resulting in avoidable hospitalizations that are estimated to cost $100 billion annually. For example, as many as 86,000 premature deaths each year are attributable to nonadherence with antihypertensive agents.2 In a meta-analysis, Cramer and Rosenheck3 found adherence with antipsychotics to be lower than with other medications, including nonpsychiatric treatments and antidepressants. The mean adherence rate with antipsychotic medications, calculated from 24 studies, was 58%, with a range from 24% to 90%. By comparison, adherence was 65% with antidepressants and 76% with treatments for nonpsychiatric disorders. The true difference between adherence rates with antipsychotics compared with other medications may be even greater because, in these studies, adherence with antipsychotics was estimated primarily by patient self-report and clinician judgment, both of which tend to overstate adherence; however, adherence rates in nonpsychiatric patients were obtained from studies that used microelectronic monitoring. As the new federal health care reform focuses the attention of policymakers upon improved outcomes and more efficient use of health care resources, enhancing adherence is a priority for clinical research and practice.

For Clinical Use

  • Adherence to medication is low in patients with schizoaffective disorder and schizophrenia and is difficult to assess without objective evidence.
  • Poor treatment adherence leads to increased rates of relapse and rehospitalization.
  • Strategies such as electronic monitoring of pill bottle openings, simplified dosing, supervised medication taking, reminder systems, depot medications, and psychotherapeutic interventions can increase adherence.
  • Patients’ attitude toward treatment and strength of the therapeutic alliance greatly influences adherence to treatment.


Accurate measurement of adherence is central to understanding the magnitude of the problem, identifying contributing factors, and assessing the effectiveness of interventions. Several methods of measuring and defining adherence exist, each with its own set of limitations.4 Patient self-report and clinician estimates of adherence, in particular, have been shown to be unreliable and increasingly are supplemented by more direct or objective measures, such as pharmacy fill rates of patients’ prescriptions, pill counts (in which patients bring pills to a clinician to be counted or home visits are made to count the pills), and electronic monitoring.5

When patients fill their prescriptions within a closed pharmacy network, over time the number of days that elapse between each prescription refill provides a means of calculating the number of missed doses. For example, if a patient returns to fill a prescription 40 days after a 30-day supply of medication was dispensed, it is estimated that the patient missed 25% of prescribed doses during the 40-day period.

Alternatively, electronic monitoring with Medication Event Monitoring System (MEMS) technology uses microchips that record the time of each opening of the pill bottle. This approach is predicated on the assumption that pill bottle openings correlate with ingesting the appropriate dose, which appears to be a relatively reliable assumption under most conditions. However, early studies using electronic monitoring in medical patients demonstrated the importance of extended periods of measurement because adherence rates often vary over time. For example, a long-term study6 of patients with epilepsy demonstrated substantial improvement in adherence during the weeks immediately before and after appointments with their doctors. This finding also suggests that another common approach to evaluating adherence, ie, a single measurement of blood medication level, may be misleading, especially if the blood is drawn at a regularly scheduled doctor’s appointment.

For clinicians who do not have access to electronic monitoring, pharmacy data on prescription refill rates can provide a useful screen for identifying patients with adherence problems.7 However, clinicians generally need to obtain as much information as possible from various sources to assess an individual patient’s adherence. Velligan and colleagues4 suggested that all studies include at least 2 measures of adherence to oral antipsychotic medications, 1 of which should be a direct or objective measure such as pharmacy refill records, pill counts, or electronic monitoring. Similarly, Schooler and colleagues8 proposed a method called all source verification for the assessment of adherence in clinical trials of patients with schizophrenia. All source verification stresses the use of multiple sources of information, including pharmacy records and other medication sources (eg, samples), as well as patient self-report and judgments by clinicians, family members, and other caregivers.


In a study using electronic monitoring with MEMS caps over a 3-month period, Byerly and colleagues9 examined 25 patients with schizophrenia and schizoaffective disorder and found that 48% were nonadherent, as defined by missing more than 30% of doses. Clinicians failed to identify any of the nonadherent patients. Adherence was not a bimodal characteristic—adherence rates were evenly distributed between the 7 patients (28%) who took more than 90% of prescribed doses and the 1 patient (4%) who took less than 10%.

In a subsequent study,10 Byerly and colleagues followed 61 patients with schizophrenia and schizoaffective disorder for up to 6 months using electronic monitoring. In addition, patients and their clinicians were asked to estimate antipsychotic adherence over the previous month, and a research assistant also assessed adherence by interviewing the patient using a 3-item questionnaire. Again defining nonadherence as missing more than 30% of doses, the MEMS caps data revealed a nonadherence rate of 57%, compared with nonadherence rates of 5% as reported by patients and 7% by prescribers. The research assistants were more accurate than the patients or the prescribers and identified 54% of participants as nonadherent, with a 36% error rate that was evenly distributed between false positive labeling of nonadherence and false negative labeling of adherence.

In a similar study, Velligan and colleagues11 found that pill counts of oral antipsychotics correlated with adherence rates calculated by electronic monitoring, whereas both patient self-report and clinician estimates of adherence were weakly correlated with pill counts. Notably, clinician estimates correlated with the patient’s clinical status, suggesting that clinicians assume patients are compliant if they are doing well.

To the extent that electronic monitoring of pill bottle openings is a valid measure of adherence, these studies demonstrate that nonadherence in patients with schizoaffective disorder and schizophrenia is both common and difficult to detect. Furthermore, adherence status is not as simple as the categories of "adherent" and "nonadherent" suggest—ie, an individual’s level of adherence may vary over time and often is best captured by the term "partial adherence." For example, Valenstein et al12 found that, over a 4-year period, 18% of schizophrenia patients were consistently nonadherent, 43% were inconsistently adherent, and 39% were consistently adherent. Finally, the tendency for patients and clinicians to greatly overestimate adherence has implications for researchers and clinicians alike. The fact that research assistants obtained a markedly less biased estimate of adherence suggests that the special interaction between patient and clinician promotes exaggeration of compliance—most likely a reflection of patients’ fears of disappointing their physician.

Studies using pharmacy fill rates have produced results similar to those of the studies using electronic monitoring. Dolder and colleagues13 examined 288 Veterans Affairs outpatients with schizophrenia or schizoaffective disorder to determine if adherence rates were improved with second-generation compared with first-generation oral antipsychotics. At 12 months, cumulative mean gap ratios were 23.2% for first-generation agents and 14.1% for second-generation agents, meaning that patients treated with first-generation agents were without medication on average 7 days per month compared with 4 days per month for those taking second-generation agents. Subsequent studies have found similar rates of adherence but have not detected an advantage with second-generation versus first-generation antipsychotics. For example, using a Medicaid claims database, Gilmer and colleagues14 found that 41% of patients with schizophrenia were adherent, 24% were nonadherent, 16% were partially adherent, and 19% were "excess fillers" of antipsychotic prescriptions, with no difference between first- and second-generation antipsychotics. Adherent patients had the lowest rate of hospitalization, nonadherent patients had the highest rate, and patients who were partially adherent or were excess fillers had intermediate rates of hospitalization.

Studies of adherence rates with antipsychotic medication have generally combined patients with diagnoses of schizophrenia and schizoaffective disorder. Only 1 published study15 differentiated adherence between the 2 diagnostic groups. Using Medicaid claims data from 55,330 patients, Olfson and colleagues did not find a significant difference in adherence with antipsychotic medication between diagnostic groups; 59.2% of patients with schizoaffective disorder versus 63.8% of patients with schizophrenia achieved at least 70% adherence, according to antipsychotic prescription refill rates. The nonsignificantly lower adherence rate among schizoaffective disorder patients occurred in the presence of higher rates of prescriptions for mood stabilizers, antidepressants, and anxiolytics and higher rates of substance abuse and hospitalization. Given the greater rates of potential cumulative medication side effects and of psychiatric morbidity, the small decrement in antipsychotic adherence rates associated with schizoaffective disorder is not surprising. Estimates of adherence with long-term treatment with mood stabilizers have ranged from 20% to 60%,16 and the median time to discontinuation after patients with bipolar disorder were first prescribed lithium was approximately 2 months in one study.17 Substance abuse substantially increases the risk of nonadherence in patients with bipolar disorder or schizophrenia; in one study,18 substance abuse decreased lifetime adherence with mood stabilizers from 82.5% to 65.5%.

Consequences of Nonadherence

Partial adherence or nonadherence has been associated with a range of poor clinical outcomes in patients with schizophrenia and schizoaffective disorder, including higher rates of emergency room visits, hospitalizations, and suicide.14,19-21 Robinson and colleagues22 found that nonadherence following a first episode of psychosis increased the risk of relapse 5-fold. Of great concern is the impact of surreptitious nonadherence upon clinical decision making. In the presence of undetected partial compliance, attempts by clinicians to titrate medication dosage can result in excessive doses when the patient resumes full adherence. Additionally, clinicians may incorrectly attribute a patient’s relapse to a lack of efficacy of the current medication and switch antipsychotics or institute polypharmacy, whereas the more appropriate response would be to improve adherence and maintain monotherapy. This dilemma can often be resolved by close supervision of medication administration using rapidly-dissolving formulations or depot injections, which allow the clinician to know with certainty whether adherence has played a role in relapse.

Factors Contributing to Nonadherence

In a review of almost 12,000 publications about adherence in medical and psychiatric patients, Blackwell23 concluded that adherence was related to patient satisfaction with treatment, continuity of care, and insight regarding the need for treatment. Nonadherence was associated with chronicity of illness, complicated treatment regimens, medication side effects, and poor social functioning. Adherence in individuals with schizophrenia and schizoaffective disorder appears to reflect a similar constellation of factors, although greater limitations in insight and psychosocial functioning may produce greater challenges. In addition, nonadherence among patients with schizophrenia and schizoaffective disorder has been associated with cognitive impairment, depression, substance abuse, inadequate discharge planning or aftercare environment, poor therapeutic alliance, and lack of family support (Table 1).24-28

Table 1

Click figure to enlarge

Studies of hypertension have established that increased complexity of medication schedules adversely affects adherence rates. This relationship was also demonstrated by Diaz and colleagues29 in a sample of 50 patients with schizophrenia and schizoaffective disorder whose medication adherence was monitored by MEMS caps for 3 months following discharge from the hospital. Adherence rates were significantly higher among patients taking an antipsychotic with once-daily dosing (62%) compared with those taking a medication requiring twice-daily dosing (26%).

Other studies of factors that mediate adherence have used less reliable measures, such as patient self-report and clinician estimates of adherence. However, attitude and insight are mediating factors that can be measured. Negative patient attitudes toward medication, which can be measured by the Drug Attitude Inventory,30 consistently predict nonadherence and drug discontinuation.31 Freudenreich and colleagues32 found that positive attitudes toward antipsychotic medications did not differ between first- and second-generation agents but were most strongly predicted by the level of insight into the illness, as measured by the Scale for the Unawareness of Illness.33 Examples of items assessing insight and attitude in the Drug Attitude Inventory include "By staying on my medication I can prevent getting sick" and "The good things about my medication outweigh the bad." Insight, in turn, has been reported to be predicted not by IQ or level of executive functioning but by greater levels of depression and anxiety.34 It is unclear whether patients become dysphoric in response to the realization that they have a serious mental illness or the presence of dysphoria makes psychotic patients more receptive to the possibility that they have a psychiatric illness. The relationship between insight and dysphoria has been found to be mediated by ratings of perceived stigma, possibly suggesting that dysphoria is a consequence of insight in individuals with negative views regarding the consequences of having the illness.35

Freudenreich and colleagues32 found that negative attitudes according to the Drug Attitude Inventory reflected the presence of side effects (ie, "Medications make me feel tired and sluggish"), lack of insight (ie, "I take my medication only when I am sick"), and issues of autonomy (ie, "It is unnatural to be controlled my medication"). Paradoxically, patients with higher levels of functioning as measured by the Quality of Life Scale had more negative attitudes toward medication. While clinicians might hope that recovered patients will attribute their functional success to treatment, as they reenter society, they may be more likely to resent medication and the stigma of continued psychiatric treatment; hence, close monitoring and support are critical during this transitional period. The importance of autonomy was also demonstrated by Day and colleagues,36 who found that perceived coercion was associated with nonadherence, in addition to poor insight and a negative therapeutic alliance.

By applying the health belief model to adherence in schizophrenia and schizoaffective disorder, clinicians understand that patients make decisions about adherence based on an assessment of perceived benefits versus disadvantages (ie, risks, side effects, and costs) of the medication—a process that occurs within the context of the patient’s capacity to recognize that he or she has an illness in need of treatment and the capacity to perceive therapeutic benefit.37 Clinicians need to appreciate that this decision process reflects the patient’s perceptions and not the clinician’s expectations. For example, in a 12-month longitudinal study38 of 409 patients with chronic schizophrenia, clinician assessment of adherence did not correlate with patient self-report. Clinicians rated adherence highest in patients who were treated for a long duration and with second-generation antipsychotics. In contrast, patient self-reports of adherence were predicted by severity of side effects. Only ratings of psychopathology predicted both clinician and patient estimates of adherence.

Assessment of treatment benefits versus adverse effects is illustrated by a path analysis study by Staring and colleagues,39 who examined the relationship between medication compliance (as rated by a caregiver) and the patient’s perceived quality of life. Increased medication compliance was associated not only with a reduction in positive symptoms but also with increased side effects. Increased burden of side effects had a greater impact on patients’ ratings of their quality of life than did improvement in psychotic symptoms, thus negating any potential positive relationship between compliance and quality of life. From a clinician’s vantage point, the reduction in psychotic symptoms might constitute a clear benefit of treatment. Only by fully understanding the patient’s experience of side effects and of symptomatic relief can a clinician appreciate the processes underlying drug attitude, insight, and adherence.

Individual patients differ substantially in their vulnerability to specific drug side effects and in the distress that they experience in response to the side effect. Antipsychotic side effects that have been associated with poor adherence include parkinsonism, akathisia, sedation, weight gain, and sexual side effects.40 Sexual side effects have been reported to be particularly distressing in young male patients.31 Weiden and colleagues41 found that obese patients treated with antipsychotics reported high rates of dissatisfaction and recent nonadherence. In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, 14.9% of subjects discontinued their initial medication due to intolerable side effects; weight gain and extrapyramidal side effects were common causes of discontinuation, whereas sedation was less commonly associated with discontinuation.42 In a study43 of patients with first-episode schizophrenia and schizoaffective disorder, extrapyramidal side effects also significantly increased medication discontinuation during the first year of treatment.

Interventions to Improve Adherence

Several strategies are available to aid clinicians in improving patients’ treatment adherence (Table 2). In a review of 39 randomized controlled studies published from 1967 to 2001, McDonald and colleagues44(p2868) concluded, "Current methods of improving medication adherence for chronic health problems are mostly complex, labor-intensive, and not predictably effective." Most of the effective interventions included combinations of simplified dosing, information, counseling, reminders, self-monitoring, reinforcement, family therapy, and additional supervision or attention. Dolder and colleagues45 reviewed interventions in patients with schizophrenia and schizoaffective disorder and found that 15 of 23 interventions moderately improved adherence. Interventions limited to education were least effective. Successful interventions combined educational, behavioral, and affective strategies, were of longer duration, and emphasized the therapeutic alliance.

Table 2

Click figure to enlarge

In a recent editorial, Cutler and Everett1 recommended 4 health policy changes to encourage adherence. They suggested removal of financial barriers such as pharmacy copayments, the development of information systems to track pharmacy refills and other relevant data, the remuneration of health care providers by outcomes rather than by fee-for-service, and an increase in the use of screening tools to identify patients at risk for nonadherence.

For the clinician working with a patient with schizoaffective disorder, the therapeutic alliance is pivotal in helping the patient accept and adhere to antipsychotic treatment. Principles of compliance therapy, a cognitive-behavioral therapy approach developed by Kemp and colleagues,46 include facilitating the patient’s acknowledgment of illness, making analogies with maintenance treatment for medical illness (eg, high blood pressure), encouraging the patient to express his or her misgivings about medications, and guiding the process of weighing therapeutic benefits against side effects. Similarly, the patient’s life goals should be explored, and the role of medication in achieving these goals should be emphasized. This approach draws heavily on the principles of motivational interviewing, which examines a patient’s motivation to change behavior and was developed for the treatment of substance abuse.47 In a randomized controlled trial,48 4 to 6 sessions of compliance therapy significantly improved compliance and reduced relapse during 18 months following hospital discharge in 74 schizophrenia and schizoaffective disorder patients. However, a large multicenter effectiveness trial49 failed to find greater benefit of compliance therapy when compared with health education. Cognitive-behavioral therapy has been reported to improve adherence in several controlled trials.50

Shared decision making has received growing support in all areas of medicine. This patient-centered approach emphasizes providing information about medications to the patient, understanding the patient’s values and beliefs about medication, and involving the patient in the decision-making process. The dialogue between the clinician and the patient should be revisited regularly during the course of long-term treatment.

Medications should be selected on an individualized basis to minimize side effects and maximize perceived benefit. A patient with schizophrenia or schizoaffective disorder may derive a sense of well-being from medication, particularly if insomnia, anxiety, or depression are alleviated in addition to the antipsychotic effects.51 A positive sense of well-being may follow immediately from medication effects on insomnia and anxiety, but considerable time and effort may be required to help a patient recognize delayed benefits, such as the prevention of relapse or improvement in social and occupational functioning. Some patients may engage in multiple episodes of nonadherence that result in relapse before the benefit of medication is acknowledged. An even higher level of insight is required to link medication to the attainment of life goals, which is an appropriate focus for cognitive-behavioral therapy.

Other interventions to enhance adherence emphasize involvement of family members and other caregivers as well as behavioral approaches. Simplification of medication regimens, ideally to a schedule of once-daily dosing, along with supervised medication administration, can markedly improve adherence. Directly observed therapy is widely used in the treatment of infectious disorders like tuberculosis or HIV in which adherence is critical.52,53 In directly observed therapy, a trained health care worker delivers and verifies the medication, checks with the patient for side effects, watches the patient swallow the medication, and documents the visit. For psychotic patients who do not live in a supervised setting, directly observed therapy can be implemented by visiting nurses or outreach workers.

In a novel approach, Cramer and Rosenheck54 used electronic monitoring with MEMS caps to review adherence with patients at monthly visits. Records of bottle openings were used in a nonjudgmental, problem-solving approach to identify obstacles to adherence. In a controlled trial,54 patients randomly assigned to receive this intervention exhibited significantly higher rates of adherence (76% vs 57%) at 6 months compared with patients receiving treatment as usual.

Cognitive adaptation training, an intervention that uses environmental supports such as signs, checklists, and alarms to cue and sequence adaptive behaviors in the home, was shown to be more effective than treatment as usual in 95 outpatients with schizophrenia.55

A new approach, information technology-aided relapse prevention, uses a cellular phone-based telemonitoring system that allows clinicians to monitor adherence and early signs of relapse. In one study,56 weekly remote monitoring reduced hospitalizations by 60% compared with a historical control.

An additional potential approach is the use of financial incentives, which have been used successfully to improve adherence in patients with substance abuse and nonpsychiatric disorders.57 Two small, uncontrolled trials57,58 of financial incentives have shown promise in patients with schizophrenia, but ethical concerns must be addressed if this strategy is to be used in patients with major psychiatric disorders.59,60

Several studies have demonstrated lower rates of relapse with first-generation depot antipsychotics compared with oral agents, particularly after the first year of follow-up.61 Depot administration lowers relapse by improving adherence and minimizes cumulative antipsychotic exposure; the use of depot agents provides clinicians with accurate information about patients’ level of adherence. Studies comparing depot preparations of second-generation antipsychotics with oral agents are in progress but have not yet been reported. Finally, long-acting oral medications, such as aripiprazole, which has a half-life of about 72 hours, achieve steady-state blood levels that are less affected by missed doses than medications with short half-lives.62

To better match specific adherence-enhancing interventions with specific patient needs, Velligan and colleagues63 recently proposed a 3-tier approach to adherence that is based on Gordon’s 3 levels of prevention used in medicine (ie, universal, selective, and indicated prevention).64 In this model, all patients with schizophrenia receive universal prevention in the form of psychoeducation and systems-based interventions that are thought to generally improve and support adherence. Those patients at high risk for nonadherence receive stepped-up care in the form of selected interventions (eg, pill boxes, enlisting family help). Patients known to be nonadherent receive interventions like directly observed therapy.


Poor adherence is common in patients with schizophrenia and schizoaffective disorder, may vary considerably over time, and is difficult for clinicians to detect. In the face of unrecognized incomplete adherence, attempts by the clinician to titrate the medication dose may be counterproductive and responses to relapse may be misguided. Many factors contribute to nonadherence, including poor insight, a negative attitude toward medication, substance abuse, and disorganization. Clinicians need to understand the patient’s assessment of medication benefits and disadvantages and work in collaboration with the patient to select medication that will provide a sense of well-being while minimizing side effects. Ultimately, the challenge is to help patients appreciate the long-term benefits of medication, including relapse prevention, improved functioning, and attainment of their life goals.

Drug names: aripiprazole (Abilify).

Disclosure of off-label usage: Dr Goff has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents that is outside US Food and Drug Administration−approved labeling has been presented in this article.


1. Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553-1555. PubMed doi:10.1056/NEJMp1002305

2. Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff (Millwood). 2007;26(1):97-110. PubMed doi:10.1377/hlthaff.26.1.97

3. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201. PubMed

4. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724-742. PubMed doi:10.1093/schbul/sbj075

5. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-1090, discussion 1073. PubMed doi:10.1016/S0149-2918(99)80026-5

6. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-1510. PubMed doi:10.1001/archinte.150.7.1509

7. Woltmann EM, Valenstein M, Welsh DE, et al. Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psychiatr Serv. 2007;58(6):864-867. PubMed doi:10.1176/

8. Schooler NR, Sunakawa A, Weiden PJ. All source verification: a new tool for measuring adherence in chronic schizophrenia. (Abstract presented at the 12th International Congress on Schizophrenia Research [ICOSR]) Schizophr Bull. 2009;35(suppl 1):366.

9. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133(2-3):129-133. PubMed doi:10.1016/j.psychres.2004.11.002

10. Byerly MJ, Thompson A, Carmody T, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv. 2007;58(6):844-847. PubMed doi:10.1176/

11. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-1192. PubMed doi:10.1176/

12. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542-1550. PubMed doi:10.4088/JCP.v67n1008

13. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103-108. PubMed doi:10.1176/appi.ajp.159.1.103

14. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699. PubMed doi:10.1176/appi.ajp.161.4.692

15. Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv. 2009;60(2):210-216. PubMed doi:10.1176/

16. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand. 2000;101(2):119-124. PubMed doi:10.1034/j.1600-0447.2000.90061.x

17. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153(8):993-1000. PubMed

18. Manwani SG, Szilagyi KA, Zablotsky B, et al. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry. 2007;68(8):1172-1176. PubMed doi:10.4088/JCP.v68n0802

19. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639. PubMed doi:10.1097/00005650-200208000-00002

20. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891. PubMed doi:10.1176/

21. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187(1):9-20. PubMed doi:10.1192/bjp.187.1.9

22. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544-549. PubMed

23. Blackwell B. From compliance to alliance: a quarter century of research. Neth J Med. 1996;48(4):140-149. PubMed

24. Ascher-Svanum H, Zhu B, Faries D, et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7):1114-1123. PubMed doi:10.4088/JCP.v67n0715

25. Perkins DO, Gu H, Weiden PJ, et al, for the Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-113. PubMed doi:10.4088/JCP.v69n0114

26. Jeste SD, Patterson TL, Palmer BW, et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res. 2003;63(1-2):49-58. PubMed doi:10.1016/S0920-9964(02)00314-6

27. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909. PubMed

28. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? a systematic review. Psychol Med. 2003;33(7):1149-1160. PubMed doi:10.1017/S0033291703008328

29. Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354-360. PubMed doi:10.4088/JCP.v65n0311

30. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183. PubMed doi:10.1017/S0033291700050182

31. Gaebel W, Riesbeck M, von Wilmsdorff M, et al, for the EUFEST Study Group. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20(5):310-316. PubMed doi:10.1016/j.euroneuro.2010.02.001

32. Freudenreich O, Cather C, Evins AE, et al. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004;65(10):1372-1376. PubMed doi:10.4088/JCP.v65n1012

33. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51(10):826-836. PubMed

34. Freudenreich O, Deckersbach T, Goff DC. Insight into current symptoms of schizophrenia: association with frontal cortical function and affect. Acta Psychiatr Scand. 2004;110(1):14-20. PubMed doi:10.1111/j.1600-0447.2004.00319.x

35. Staring AB, Van der Gaag M, Van den Berge M, et al. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophr Res. 2009;115(2-3):363-369. PubMed doi:10.1016/j.schres.2009.06.015

36. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717-724. PubMed doi:10.1001/archpsyc.62.7.717

37. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121-1128. PubMed

38. Barbui C, Kikkert M, Mazzi MA, et al. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42(5):311-317. PubMed doi:10.1159/000232973

39. Staring AB, Mulder CL, Duivenvoorden HJ, et al. Fewer symptoms vs more side-effects in schizophrenia? opposing pathways between antipsychotic medication compliance and quality of life. Schizophr Res. 2009;113(1):27-33. PubMed doi:10.1016/j.schres.2009.05.022

40. Fleischhacker WW, Meise U, Günther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994;382:11-15. PubMed

41. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57. PubMed doi:10.1016/S0920-9964(02)00498-X

42. Lieberman JA. Comparative effectiveness of antipsychotic drugs: a commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry. 2006;63(10):1069-1072. PubMed doi:10.1001/archpsyc.63.10.1069

43. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2-3):209-219. PubMed doi:10.1016/S0920-9964(01)00312-7

44. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868-2879. PubMed doi:10.1001/jama.288.22.2868

45. Dolder CR, Lacro JP, Leckband S, et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol. 2003;23(4):389-399. PubMed doi:10.1097/

46. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345-349. PubMed

47. Miller WR, Rollnick S, eds. Motivational Interviewing: Preparing People for Change. 2nd ed. New York, NY: Guilford Press; 2002.

48. Kemp R, Kirov G, Everitt B, et al. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998;172(5):413-419. PubMed doi:10.1192/bjp.172.5.413

49. Gray R, Leese M, Bindman J, et al. Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br J Psychiatry. 2006;189(6):508-514. PubMed doi:10.1192/bjp.bp.105.019489

50. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry. 2006;163(3):365-373. PubMed doi:10.1176/appi.ajp.163.3.365

51. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1-2):79-88. PubMed doi:10.1016/S0920-9964(00)00166-3

52. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005;293(22):2776-2784. PubMed doi:10.1001/jama.293.22.2776

53. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167-179. PubMed

54. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis. 1999;187(1):53-55. PubMed doi:10.1097/00005053-199901000-00009

55. Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34(3):483-493. PubMed doi:10.1093/schbul/sbm111

56. Š paniel F, Vohlí­dka P, Hrdlička J, et al. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res. 2008;98(1-3):312-317. PubMed doi:10.1016/j.schres.2007.09.005

57. Giuffrida A, Torgerson DJ. Should we pay the patient? review of financial incentives to enhance patient compliance. BMJ. 1997;315(7110):703-707. PubMed

58. Staring AB, Mulder CL, Priebe S. Financial incentives to improve adherence to medication in five patients with schizophrenia in the Netherlands. Psychopharmacol Bull. 2010;43(1):5-10. PubMed

59. Claassen D. Financial incentives for antipsychotic depot medication: ethical issues. J Med Ethics. 2007;33(4):189-193. PubMed doi:10.1136/jme.2006.016188

60. Szmukler G. Financial incentives for patients in the treatment of psychosis. J Med Ethics. 2009;35(4):224-228. PubMed doi:10.1136/jme.2008.027151

61. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64(Suppl 16):14-17. PubMed

62. Goff DC. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients’ quality of life. Am J Psychiatry. 2008;165(8):940-943. PubMed doi:10.1176/appi.ajp.2008.08050673

63. Velligan D, Sajatovic M, Valenstein M, et al. Methodological challenges in psychiatric treatment adherence research. Clin Schizophr Relat Psychoses. 2010;4(1):74-91. PubMed doi:10.3371/CSRP.4.1.6

64. Gordon RS Jr. An operational classification of disease prevention. Public Health Rep. 1983;98(2):107-109. PubMed

Related Articles

Volume: 71

Quick Links: Bipolar Disorder , Mood Disorders